tirzepatide and gallbladder Does Zepbound Cause Issues? Risks Symptoms tirzepatide pancreatitis gallbladder disease risk

doi:10.1080/14740338.2023.1163965 Dahl, D., Onishi, Y., Norwood, P., Huh, R., & Bray, R

In the SURMOUNT-5 trial, tirzepatide produced an average weight reduction of 20.2% (about 50 lbs) over 72 weeks, compared with 13.7% (about 33 lbs) for injectable semaglutide

Tirzepatide is a synthetic peptide with a novel dual-agonist architecture - a single molecule designed to engage both GLP-1R and GIPR simultaneously

Study link: Not too fast, before we clap, we should approach this models benefit w causion

Additionally, regular follow-ups can help in fine-tuning the dosage and addressing any emerging concerns, ultimately leading to a more personalized and effective treatment strategy